{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:53:14Z","timestamp":1783021994156,"version":"3.54.6"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Therapeutic options may be limited for patients with psoriasis who have concomitant liver disease (PsL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We aimed to report the frequency of liver disease among patients with psoriasis, and describe the clinical features, treatment modalities and quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicentre cross-sectional study of patients with psoriasis notified to the Malaysian Psoriasis Registry (MPR) from January 2007 to December 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 21 735 patients with psoriasis, 174 (0.8%) had liver disease. The three most common liver diseases were viral hepatitis (62.1%), fatty liver (14.4%) and liver cirrhosis (10.9%). The male-to-female ratio was 3.8 : 1. Mean age (SD) of onset of psoriasis was higher in those with liver disease vs. those without [37.25\u2005years (13.47) vs. 33.26\u2005years (16.96), P &amp;lt; 0.001]. Patients with PsL, compared with those without liver disease, had a higher rate of dyslipidaemia (27.5% vs. 16.4%, P &amp;lt; 0.001), hypertension (33.9% vs. 23.7%, P = 0.002), diabetes mellitus (22.4% vs. 15.9%, P = 0.021) and HIV infection (5.3% vs. 0.4%, P &amp;lt; 0.001). Those with PsL were also more likely than those without liver disease to have severe disease [body surface area &amp;gt; 10% and\/or Dermatology Life Quality Index (DLQI) &amp;gt; 10] (59.3% vs. 49.9%, P = 0.027), psoriatic arthropathy (21.1% vs. 13.0%, P = 0.002) and nail involvement (78.2% vs. 56.1%, P &amp;lt; 0.001). Also significantly higher in the group with PsL were the use of phototherapy (8.4% vs. 2.6%, P &amp;lt; 0.001), acitretin (7.3% vs. 2.8%, P &amp;lt; 0.001) and ciclosporin (3.0% vs. 0.7%, P &amp;lt; 0.001). Mean DLQI was similar in both groups [9.69 (7.20) vs. 9.62 (6.75), P = 0.88].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The frequency of patients with PsL in the MPR was 0.8%. Patients with PsL were more likely to be male, had a higher rate of comorbidities, severe disease, and nail and joint involvement than those without liver disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad013","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T04:02:26Z","timestamp":1673496146000},"page":"476-483","source":"Crossref","is-referenced-by-count":2,"title":["Liver disease among patients with psoriasis: the Malaysian Psoriasis Registry"],"prefix":"10.1093","volume":"48","author":[{"given":"Y T","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Sultanah Aminah, Ministry of Health Malaysia , Johor Bahru , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia , Kuala Lumpur , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur, Ministry of Health Malaysia , Kuala Lumpur , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Malaysian Psoriasis Registry Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"2023100416443850000_llad013-B1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.17235\/reed.2019.6263\/2019","article-title":"Psoriasis and fatty liver: a harmful synergy","volume":"111","author":"Olveira","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"2023100416443850000_llad013-B2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/ajd.12460","article-title":"Psoriasis and the liver: problems, causes and course","volume":"58","author":"Tula","year":"2017","journal-title":"Australas J Dermatol"},{"key":"2023100416443850000_llad013-B3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/TJD.TJD_42_20","article-title":"Hepatitis B virus reactivation in patients with psoriasis on biologic therapies: a retrospective study","volume":"14","author":"\u00d6z\u00e7elik","year":"2020","journal-title":"Turkish J Dermatol"},{"key":"2023100416443850000_llad013-B4","first-page":"370","article-title":"How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations","volume":"17","author":"Pan","year":"2008","journal-title":"Asia Pac J Clin Nutr"},{"key":"2023100416443850000_llad013-B5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100416443850000_llad013-B6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing non-alcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"2023100416443850000_llad013-B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"2023100416443850000_llad013-B8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2023100416443850000_llad013-B9","author":"Ministry of Health Virtual Library."},{"key":"2023100416443850000_llad013-B10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1440-1746.2011.06732.x","article-title":"Liver cirrhosis in Malaysia: peculiar epidemiology in a multiracial Asian country","volume":"26","author":"Qua","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"2023100416443850000_llad013-B11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/MCG.0000000000000208","article-title":"The epidemiology of cirrhosis in the United States: a population-based study","volume":"49","author":"Scaglione","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"2023100416443850000_llad013-B12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","article-title":"Chronic hepatitis B virus infection in Asian countries","volume":"15","author":"Merican","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"2023100416443850000_llad013-B13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12072-012-9359-2","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia","volume":"7","author":"Goh","year":"2013","journal-title":"Hepatol Int"},{"key":"2023100416443850000_llad013-B14","doi-asserted-by":"crossref","first-page":"e0181039","DOI":"10.1371\/journal.pone.0181039","article-title":"An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies","volume":"12","author":"Singh","year":"2017","journal-title":"PLoS One"},{"key":"2023100416443850000_llad013-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"2023100416443850000_llad013-B16","doi-asserted-by":"crossref","first-page":"e304\u201310","DOI":"10.1111\/ajd.13098","article-title":"Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk","volume":"60","author":"Romero-P\u00e9rez","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"217","key":"2023100416443850000_llad013-B17","article-title":"Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis?","volume":"17","author":"Mantovani","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2023100416443850000_llad013-B18","first-page":"517","article-title":"Non-alcoholic fatty liver disease and psoriasis \u2013 is there a shared proinflammatory network?","volume":"19","author":"Heitmann","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023100416443850000_llad013-B19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/jdv.12847","article-title":"Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis","volume":"29","author":"Candia","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416443850000_llad013-B20","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.3748\/wjg.v22.i28.6444","article-title":"Management of psoriasis patients with hepatitis B or hepatitis C virus infection","volume":"22","author":"Bonifati","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2023100416443850000_llad013-B21","article-title":"Liver illness and psoriatic patients","volume":"3140983","author":"Fiore","year":"2018","journal-title":"Biomed Res Int"},{"key":"2023100416443850000_llad013-B22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-016-0211-7","article-title":"Considerations for systemic treatment of psoriasis in obese patients","volume":"17","author":"Gisondi","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"2023100416443850000_llad013-B23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/01480545.2010.483519","article-title":"Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats","volume":"34","author":"Erarslan","year":"2011","journal-title":"Drug Chem Toxicol"},{"key":"2023100416443850000_llad013-B24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient. Psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2023100416443850000_llad013-B25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2009.06.008","article-title":"Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Miele","year":"2009","journal-title":"J Hepatol"},{"key":"2023100416443850000_llad013-B26","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris \u2013 Update 2015 \u2013 Short version \u2013 EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416443850000_llad013-B27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjd.14899","article-title":"Physical activity and lifestyle improvement in the management of psoriasis","volume":"175","author":"Schmitt-Egenolf","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023100416443850000_llad013-B28","doi-asserted-by":"crossref","first-page":"e69-72","DOI":"10.1111\/j.1440-0960.2011.00767.x","article-title":"Generalized flare of pustular psoriasis induced by PEGylated interferon-\u03b12b therapy for chronic hepatitis C","volume":"53","author":"Wu","year":"2012","journal-title":"Australas J Dermatol"},{"key":"2023100416443850000_llad013-B29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","article-title":"Managing psoriasis in patients with HBV or HCV infection: practical considerations","volume":"20","author":"Piaserico","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2023100416443850000_llad013-B30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/09546634.2019.1657225","article-title":"How do we treat psoriasis patients with hepatitis C infections in real-world situations? A retrospective analysis of 34 patients","volume":"32","author":"Chularojanamontri","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2023100416443850000_llad013-B31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1196\/annals.1423.058","article-title":"Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection","volume":"1110","author":"Galeazzi","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2023100416443850000_llad013-B32","first-page":"63","article-title":"Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?","volume":"13","author":"Manna","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2023100416443850000_llad013-B33","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jdv.16683","article-title":"Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416443850000_llad013-B34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2133.1990.tb02890.x","article-title":"Methotrexate side-effects","volume":"122","author":"Zachariae","year":"1990","journal-title":"Br J Dermatol"},{"key":"2023100416443850000_llad013-B35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2018.05.004","article-title":"Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan","volume":"79","author":"Tang","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100416443850000_llad013-B36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023100416443850000_llad013-B37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100416443850000_llad013-B38","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2023100416443850000_llad013-B39","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jdv.12255","article-title":"Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study","volume":"28","author":"Montaudi\u00e9","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416443850000_llad013-B40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","article-title":"Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment","volume":"24","author":"Renzo","year":"2011","journal-title":"Dermatol Ther"},{"key":"2023100416443850000_llad013-B41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ajd.12044","article-title":"Weight gain and tumor necrosis factor-alpha inhibitors in patients with psoriasis","volume":"54","author":"Tan","year":"2013","journal-title":"Australas J Dermatol"},{"key":"2023100416443850000_llad013-B42","doi-asserted-by":"crossref","first-page":"17352","DOI":"10.3748\/wjg.v20.i46.17352","article-title":"Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management","volume":"20","author":"Rossi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2023100416443850000_llad013-B43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023100416443850000_llad013-B44","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1007\/s10620-018-5023-6","article-title":"Acute liver failure from tumor necrosis factor-\u03b1 antagonists: report of four cases and literature review","volume":"63","author":"Kok","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2023100416443850000_llad013-B45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100416443850000_llad013-B46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100416443850000_llad013-B47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaad.2019.12.001","article-title":"Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study","volume":"85","author":"Chiu","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100416443850000_llad013-B48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/09546634.2018.1430301","article-title":"Safety of biologic agents for psoriasis in patients with viral hepatitis","volume":"29","author":"AlMutairi","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"2023100416443850000_llad013-B49","doi-asserted-by":"crossref","first-page":"e14008","DOI":"10.1111\/dth.14008","article-title":"Impact of long-term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection","volume":"33","author":"Chularojanamontri","year":"2020","journal-title":"Dermatol Ther"},{"key":"2023100416443850000_llad013-B50","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad013\/49297847\/llad013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/5\/476\/51854790\/llad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/5\/476\/51854790\/llad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T12:45:24Z","timestamp":1696423524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/5\/476\/6985910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,1,12]]},"published-print":{"date-parts":[[2023,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad013","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,1,12]]}}}